Sagimet Biosciences Inc - Class A

Research Sagimet Biosciences Inc - Class A (SGMT) on Bullrun: market cap USD 253.84M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerSGMT
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 253.84M
• Financial periodFY2025
• Net income-USD 51.04M

Valuation Snapshot

latest market cap is USD 253.84M.

About Sagimet Biosciences Inc - Class A

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer.

Frequently asked questions

What is Sagimet Biosciences Inc - Class A's market cap?

Sagimet Biosciences Inc - Class A's market capitalization is USD 253.84M.

What does Sagimet Biosciences Inc - Class A do?

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States.